Lobbying client
AFRAXIS
Working to develop treatments for diseases of the central nervous system
Filings
6
Filed by
1
Reported in-house
—
Reported by firms
$90,000
Reported lobbying by year
The larger of in-house and firm-reported each year, $ thousands
2009 to 2010
Filings
6 filings, newest first.
| Filing | Filed by | Amount |
|---|---|---|
|
3rd Quarter - Termination Amendment 3rd Quarter 2010
|
FABIANI & COMPANY | — reported |
|
3rd Quarter - Terminationreplaced 3rd Quarter 2010
|
FABIANI & COMPANY | — reported |
|
2nd Quarter - Report 2nd Quarter 2010
|
FABIANI & COMPANY | $30,000 reported |
|
1st Quarter - Report 1st Quarter 2010
|
FABIANI & COMPANY | $30,000 reported |
|
Registration 1st Quarter 2010
|
FABIANI & COMPANY | — reported |
|
1st Quarter - Report 1st Quarter 2009
|
FABIANI & COMPANY | $30,000 reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| FABIANI & COMPANY | 4 | $90,000 |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Defense | DEF | 5 |
| Pharmacy | PHA | 5 |
| Medical/Disease Research/Clinical Labs | MED | 5 |
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.